The Alzheimer's disease assessment scale: Evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease

被引:85
作者
Doraiswamy, PM
Kaiser, L
Bieber, F
Garman, RL
机构
[1] Duke Univ, Med Ctr, Durham, NC 27710 USA
[2] Bayer Corp, West Haven, CT USA
关键词
dementia; clinical trials; neuropsychological tests; memory;
D O I
10.1097/00002093-200110000-00003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: To evaluate the psychometric properties and patterns of decline on the total score and item scores of the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog) in patients with Alzheimer Disease (AD), Methods: We analyzed data from 536 AD outpatients randomized to the placebo group in two identical 20-week multicenter drug trials. Results: Mean deterioration at week 26 on the ADAS-Cog total score for subjects with moderate dementia was 84% greater than that for those with milder severity (p < 0.001). After adjusting for this effect. age (p = 0.015) and educational level (p = 0.01) also predicted cognitive decline. In a model, absolute change for most individual ADAS items was less than 10% of the possible change. and It Was generally smaller than one-third of the standard deviation of the measure. Measurement error variability was greatest for word recognition and the "placebo" effect was greatest for word recall. Variability increased with trial duration in a model, Conclusions: There is a relationship between baseline severity and magnitude of cognitive decline. In 6-month trials. measurement error makes a substantial contribution to the variance in ADAS-Cog change scores. Sensitivity to intervention effects ill therefore depend both on the variability and magnitude of change, Such data must be considered when designing future trials to minimize measurement error variability and increase sensitivity for specific populations.
引用
收藏
页码:174 / 183
页数:10
相关论文
共 24 条
[1]  
[Anonymous], 1987, DIAGNOSTIC STAT MANU, V4th
[2]   Variability in annual mini-mental state examination score in patients with probable Alzheimer disease -: A clinical perspective of data from the consortium to establish a registry for Alzheimer's disease [J].
Clark, CM ;
Sheppard, L ;
Fillenbaum, GG ;
Galasko, D ;
Morris, JC ;
Koss, E ;
Mohs, R ;
Heyman, A .
ARCHIVES OF NEUROLOGY, 1999, 56 (07) :857-862
[3]   POPULATION-BASED NORMS FOR THE MINI-MENTAL-STATE-EXAMINATION BY AGE AND EDUCATIONAL-LEVEL [J].
CRUM, RM ;
ANTHONY, JC ;
BASSETT, SS ;
FOLSTEIN, MF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (18) :2386-2391
[4]   A DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF TACRINE FOR ALZHEIMERS-DISEASE [J].
DAVIS, KL ;
THAL, LJ ;
GAMZU, ER ;
DAVIS, CS ;
WOOLSON, RF ;
GRACON, SI ;
DRACHMAN, DA ;
SCHNEIDER, LS ;
WHITEHOUSE, PJ ;
HOOVER, TM ;
MORRIS, JC ;
KAWAS, CH ;
KNOPMAN, DS ;
EARL, NL ;
KUMAR, V ;
DOODY, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (18) :1253-1259
[5]   COGNITIVE PERFORMANCE ON THE ALZHEIMERS-DISEASE ASSESSMENT SCALE - EFFECT OF EDUCATION [J].
DORAISWAMY, PM ;
KRISHEN, A ;
STALLONE, F ;
MARTIN, WL ;
POTTS, NL ;
METZ, A ;
DEVEAUGHGEISS, J .
NEUROLOGY, 1995, 45 (11) :1980-1984
[6]   Variability of the Mini-Mental State Examination in dementia [J].
Doraiswamy, PM ;
Kaiser, L .
NEUROLOGY, 2000, 54 (07) :1538-1539
[7]   The Alzheimer's disease assessment scale: Patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials [J].
Doraiswamy, PM ;
Bieber, F ;
Kaiser, L ;
Krishnan, KR ;
ReuningScherer, J ;
Gulanski, B .
NEUROLOGY, 1997, 48 (06) :1511-1517
[8]   NSAIDs and cognition in Alzheimer's disease [J].
Doraiswamy, PM ;
Krishen, A ;
Stallone, F ;
Martin, ML ;
Potts, NLS ;
Metz, A ;
DeVeaughGeiss, J .
NEUROLOGY, 1996, 46 (04) :1194-1194
[9]  
Doraiswamy PM, 1997, PSYCHOPHARMACOL BULL, V33, P123
[10]  
DORAISWAMY PM, 1997, INT J GERIAT PSYCHOP, V1, P34